IBDEI2QD ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,43540,1,3,0)
 ;;=3^Psychomtr Dfct s/p Unsp Cebrvsc Dis
 ;;^UTILITY(U,$J,358.3,43540,1,4,0)
 ;;=4^I69.913
 ;;^UTILITY(U,$J,358.3,43540,2)
 ;;=^5138663
 ;;^UTILITY(U,$J,358.3,43541,0)
 ;;=I69.914^^160^2124^31
 ;;^UTILITY(U,$J,358.3,43541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43541,1,3,0)
 ;;=3^Front Lobe/Exec Fx Dfct s/p Unsp Crbrovs Dis
 ;;^UTILITY(U,$J,358.3,43541,1,4,0)
 ;;=4^I69.914
 ;;^UTILITY(U,$J,358.3,43541,2)
 ;;=^5138664
 ;;^UTILITY(U,$J,358.3,43542,0)
 ;;=I69.915^^160^2124^15
 ;;^UTILITY(U,$J,358.3,43542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43542,1,3,0)
 ;;=3^Cog Social/Emot Dfct s/p Crbrvsc Dis
 ;;^UTILITY(U,$J,358.3,43542,1,4,0)
 ;;=4^I69.915
 ;;^UTILITY(U,$J,358.3,43542,2)
 ;;=^5138665
 ;;^UTILITY(U,$J,358.3,43543,0)
 ;;=I69.918^^160^2124^48
 ;;^UTILITY(U,$J,358.3,43543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43543,1,3,0)
 ;;=3^Sym/Sgns Cog Fxn Dfct s/p Unsp Crbrvsc Dis,Oth
 ;;^UTILITY(U,$J,358.3,43543,1,4,0)
 ;;=4^I69.918
 ;;^UTILITY(U,$J,358.3,43543,2)
 ;;=^5138666
 ;;^UTILITY(U,$J,358.3,43544,0)
 ;;=I69.919^^160^2124^49
 ;;^UTILITY(U,$J,358.3,43544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43544,1,3,0)
 ;;=3^Sym/Sgns Cog Fxn Dfct s/p Unsp Crbrvsc Dis,Unsp
 ;;^UTILITY(U,$J,358.3,43544,1,4,0)
 ;;=4^I69.919
 ;;^UTILITY(U,$J,358.3,43544,2)
 ;;=^5138667
 ;;^UTILITY(U,$J,358.3,43545,0)
 ;;=I69.993^^160^2124^13
 ;;^UTILITY(U,$J,358.3,43545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43545,1,3,0)
 ;;=3^Ataxia following unspec Cerebrovasc Disease
 ;;^UTILITY(U,$J,358.3,43545,1,4,0)
 ;;=4^I69.993
 ;;^UTILITY(U,$J,358.3,43545,2)
 ;;=^5007571
 ;;^UTILITY(U,$J,358.3,43546,0)
 ;;=I69.998^^160^2124^16
 ;;^UTILITY(U,$J,358.3,43546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43546,1,3,0)
 ;;=3^Disturbance of Vision
 ;;^UTILITY(U,$J,358.3,43546,1,4,0)
 ;;=4^I69.998
 ;;^UTILITY(U,$J,358.3,43546,2)
 ;;=^5007572
 ;;^UTILITY(U,$J,358.3,43547,0)
 ;;=I69.992^^160^2124^29
 ;;^UTILITY(U,$J,358.3,43547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43547,1,3,0)
 ;;=3^Facial Weakness s/p Unspec Cerebrov Dis
 ;;^UTILITY(U,$J,358.3,43547,1,4,0)
 ;;=4^I69.992
 ;;^UTILITY(U,$J,358.3,43547,2)
 ;;=^5007570
 ;;^UTILITY(U,$J,358.3,43548,0)
 ;;=I69.923^^160^2124^30
 ;;^UTILITY(U,$J,358.3,43548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43548,1,3,0)
 ;;=3^Fluency Disorder s/p Unspec Cerebrov Dis
 ;;^UTILITY(U,$J,358.3,43548,1,4,0)
 ;;=4^I69.923
 ;;^UTILITY(U,$J,358.3,43548,2)
 ;;=^5007556
 ;;^UTILITY(U,$J,358.3,43549,0)
 ;;=I69.951^^160^2124^34
 ;;^UTILITY(U,$J,358.3,43549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43549,1,3,0)
 ;;=3^Hemiplegia Affecting Rt Dominant Side
 ;;^UTILITY(U,$J,358.3,43549,1,4,0)
 ;;=4^I69.951
 ;;^UTILITY(U,$J,358.3,43549,2)
 ;;=^5007561
 ;;^UTILITY(U,$J,358.3,43550,0)
 ;;=I69.952^^160^2124^32
 ;;^UTILITY(U,$J,358.3,43550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43550,1,3,0)
 ;;=3^Hemiplegia Affecting Lt Dominant Side
 ;;^UTILITY(U,$J,358.3,43550,1,4,0)
 ;;=4^I69.952
 ;;^UTILITY(U,$J,358.3,43550,2)
 ;;=^5133586
 ;;^UTILITY(U,$J,358.3,43551,0)
 ;;=I69.953^^160^2124^35
 ;;^UTILITY(U,$J,358.3,43551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43551,1,3,0)
 ;;=3^Hemiplegia Affecting Rt Non-Dominant Side
 ;;^UTILITY(U,$J,358.3,43551,1,4,0)
 ;;=4^I69.953
 ;;^UTILITY(U,$J,358.3,43551,2)
 ;;=^5007562
 ;;^UTILITY(U,$J,358.3,43552,0)
 ;;=I69.954^^160^2124^33
